Recipharm, a contract development and manufacturing organization, agreed to acquire Vibalogics, a virotherapy CDMO company, from Ampersand Capital Partners, a private equity firm. Financial terms were not disclosed. “We are excited by the opportunities that are already apparent from working with true pioneers in the area of virotherapy manufacturing. We are delighted to welcome our new colleagues from Vibalogics to Recipharm and are committed to supporting and even accelerating growth in the years to come and to continue to partner with customers in virus manufacturing solutions. This acquisition strengthens Recipharm’s presence in ATMPs and enables us to get closer to our US customers. We look forward to working with the Vibalogics team, building links across the wider Recipharm organization to make this business a huge success," Marc Funk, Recipharm CEO.